Development of regenerative therapy of central nervous system, using with asialo-erythropoietin

已知全身大剂量重组人促红细胞生成素（rhEPO）可减轻缺血性损伤。然而，大剂量rhEPO可能因其促红细胞生成作用而增加血液粘度，从而加重缺血性病变。亚洲促红细胞生成素（asialoEPO）是一种具有极短血浆半衰期的促红细胞生成素衍生物，其促红细胞生成素的作用明显小于原始促红细胞生成素。我们试图确定在沙鼠短暂性前脑缺血模型中，asia - aloepo是否具有与原始EPO相同的神经保护作用，结果表明，多次给药的asialoEPO与EPO一样，可以保护海马CA1神经元免受缺血性损伤，而不影响红细胞生成。这一数据提示，亚洲促生成素将是一种新型的神经保护剂。

Systemic administration of high-dose recombinant human erythropoietin(rhEPO) is known to attenuate ischemic injury. However, high-dose rhEPO might aggravate ischemic lesions by increasing blood viscosity because of its erythropoietic effects. Asialoerythropoietin(asialoEPO), an EPO derivative with an extremely short plasma half-life, has considerably lesser erythropoietic effect than that of naive EPO. We attempted to determine whether asialoEPO exerts the same neuroprotective effect as naive EPO in a gerbil transient forebrain ischemia model, and resulting multiple dosing of asialoEPO, like EPO, could protect the hippocampal CA1 neurons from ischemic damage without affecting erythropoiesis. This data suggested that asialoEPO would be novel neuro-protective agent in the future.